PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023, to complete the following.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年3月20日)-PreveCeutical Medical Inc.(CSE：PRIV)(OTCQB：PRVCF)(FSE：18H)(The“Company”或“PreveCeutical”)，很高興地宣佈，PreveCeutical於2023年2月7日宣佈與我們選定的臨床研究機構(CRO)開始臨床工作，以完成以下工作。
- Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond those already underway or in the planning stage) that will be needed to support a successful initial IND and/or CTA submission.
- Construction of a clinical development plan for Phase 1 through pivotal Phase 3 studies.
- Authoring of the Investigational Brochure for the Client's lead peptide in the final indication of interest.
- 進行全面的差距分析，以確認當前的結論，並確定任何潛在的額外非臨床研究(除了那些已經在進行或在規劃階段的研究)，以支持成功的初始IND和/或CTA提交。
- 構建第一階段至關鍵第三階段研究的臨床發展計劃。
- 編寫客戶最終意向指示中的先導肽的調查手冊。
PreveCeutical has now commenced the clinical development on March 20, 2023. This work is being performed at our selected CRO's facilities in Australia.
PreveCeutical現已於2023年3月20日開始臨床開發。這項工作正在我們選定的CRO在澳大利亞的設施中進行。
Furthermore, the board of directors appointed a disclosure committee represented by Stephen Van Deventer, Dr Linnea Olofsson and Evan Ballantyne effective immediately.
此外，董事會任命了一個以斯蒂芬·範·黛文特、林妮亞·奧洛夫鬆博士和埃文·巴蘭廷為代表的披露委員會，立即生效。
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "As we continue to meet further milestones, we are enthusiastic that this program has commenced as we plan to aggressively pursue the development so we may apply for IND (Investigative New Drug) status and complete the Phase 1 clinical trials."
PreveCeutical首席執行官斯蒂芬·範·黛文特先生評論說，隨著我們繼續達到更多的里程碑，我們很高興這一計劃已經開始，因為我們計劃積極地進行開發，這樣我們就可以申請IND(研究新藥)資格並完成第一階段臨床試驗。“
About PreveCeutical
關於PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
PreveCeutical是一家健康科學公司，利用有機和天然相同的產品開發預防和治療方法的創新選擇。該公司的目標是成為預防健康科學領域的領先者。
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
隨著三項研究計劃的完成，該公司正在積極開展其產品的開發、臨床試驗和商業化工作，並提交了多項臨時專利申請，以保護其研究計劃的知識產權。
For more information about PreveCeutical, please visit our website, or follow us on Twitter and Facebook.
有關PreveCeutical的更多資訊，請訪問我們的網站，或在Twitter和Facebook上關注我們。
On behalf of the Board of Directors of PreveCeutical
我代表PreveCeutical董事會
Stephen Van Deventer, Chairman and Chief Executive Officer
斯蒂芬·範·黛文特，董事長兼首席執行官
For further information, please contact:
如需更多資訊，請聯繫：
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com
史蒂芬·範·黛文特：+1 604 306 9669
或投資者關係郵箱：ir@prepreeceutical.com
Forward-Looking Statements:
前瞻性陳述：
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and US securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, matters related to the Company's current and planned research and development programs, including the Analgesic Program, the Company's anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, including the Company's research and development activities, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.
本新聞稿包含符合適用的加拿大和美國證券法的前瞻性陳述和前瞻性資訊(統稱為“前瞻性陳述”)，包括“1995年美國私人證券訴訟改革法”。本新聞稿中所有非純粹歷史性的陳述都是前瞻性陳述，包括關於對未來的信念、計劃、期望和方向的陳述，包括但不限於與公司當前和計劃的研究和開發計劃有關的事項，包括止痛藥計劃、公司預期的業務計劃以及成功執行其提議的計劃的前景。前瞻性陳述常常但不總是可以用“將”、“計劃”、“預期”、“可能”、“打算”、“預期”、“相信”、“提議”等詞語或這些詞語的變體來識別，包括其否定變體和涉及可能、可能、將會發生或將採取或實現的某些行動、事件或結果的短語。前瞻性陳述基於對公司的某些假設，包括預期增長、經營結果，包括公司的研發活動、業績、行業趨勢、增長機會，以及公司將能夠獲得開展其計劃的未來活動、留住和吸引合格研究人員以及獲得和/或維護開展其未來業務活動所需的必要知識產權所需的資金。
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the Analgesic Program, complexities and delays in connection with research and development activities and the actual results of research and development activities, and the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialize therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and product development programs as planned, including the Analgesic Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the healthcare and cannabis industries in Canada may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions, and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, intentions, or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at .
實際結果可能與任何前瞻性陳述中預測的結果不同，原因包括許多因素，包括與止痛藥計劃有關的風險和不確定因素，與研發活動和研發活動的實際結果有關的複雜性和延遲，以及公司無法獲得所需的任何必要的政府、監管或證券交易所批准、許可、同意或授權，包括加拿大證券交易所接受任何計劃的未來活動，將治療和診斷技術商業化，執行其擬議的業務計劃，尋求業務合作夥伴關係，按計劃完成其研究和產品開發計劃，包括止痛藥計劃，並獲得開展其計劃的未來活動所需的資金。其他因素，如總體經濟、市場或商業狀況或影響加拿大醫療保健和大麻行業的法律、法規和政策的變化，也可能對公司未來的業績或業績產生不利影響。這些前瞻性陳述是在本新聞稿發佈之日作出的，除非適用法律要求，否則公司沒有義務更新前瞻性陳述或更新實際結果可能與這些前瞻性陳述中預測的結果不同的原因。儘管公司相信本新聞稿中包含的陳述、信念、計劃、期望、意圖和假設是合理的，但不能保證這些陳述、信念、計劃、期望、意圖或假設將被證明是準確的。讀者應考慮本文所列的所有資訊，並應參考公司不定期提供的其他定期報告。這些報告和該公司的檔案可在以下網址查閱。
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
請讀者注意，前瞻性陳述並不是對未來業績或事件的保證，因此提醒讀者不要過度依賴前瞻性陳述，因為此類陳述本身存在不確定性。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。